Sign inJoin waitlistJoin the waitlist

NS

Neil Segal

Research Director, Division of Gastrointestinal Oncology · New York Presbyterian Hospital

Credentials: · · · · ·

History

Division of Gastrointestinal Oncology · New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
1998–2000
Internal Medicine
The Medical Center
1995–1998
PhD, University of the Witwatersrand South Africa
1991–1995

Research

Nivolumab plus ipilimumab in advanced melanoma
New England Journal of Medicine · 2013 · 3,387 citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
Immunotherapy in colorectal cancer: rationale, challenges and potential
Review · Nature Reviews Gastroenterology & Hepatology · 2019 · 1,541 citations

LS
Leonard Saltz
45 papers
AC
Andrea Cercek
40 papers
MW
Martin Weiser
39 papers
RY
Rona Yaeger
39 papers
ZS
Zsofia Stadler
38 papers
JS
Jinru Shia
36 papers
JG
Julio Garcia-Aguilar
28 papers · 8 as a fellow
Philip Paty
23 papers
Jesse Smith
22 papers
GN
Garrett Nash
21 papers
Diane Reidy-Lagunes
19 papers
EV
Efsevia Vakiani
16 papers

Clinical trials

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2025–2030
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2020–2026
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Principal investigator · Withdrawn · Phase 2
Memorial Sloan Kettering Cancer Center
2019–2021
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2017–2021